BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

DelSite Biotechnologies, Inc. Announces Intention to License Manapol(R) Manufacturing Rights, Fields of Use and Territories


2/18/2009 11:23:17 AM

IRVING, TX--(Marketwire - February 18, 2009) - DelSite, Inc (OTCBB: DSII) today announced that in order to protect its proprietary raw material Manapol® from cheap, ineffective, foreign raw materials, it has initiated a licensing program for its proprietary raw materials including Manapol®. There are currently no agreements that preclude the broad and lawful licensing of these products.

Manapol® is a biologic raw material produced as a "product by process" which ensures quality and consistency. Manapol® is used in DelSite's AloeCeuticals® product line. Manapol® is also used to fortify various nutraceutical drinks made from fresh aloe gel.

Manapol® raw material carries the DSHEA claim of "enhances the immune system." This claim is based on human clinical trials. Other clinical trials of Manapol® raw material have provided DSHEA claims on digestion and cholesterol maintenance.

A DelSite spokesperson said, "The widely held perception that one company has the exclusive right to market Manapol® is categorically not true, as is the notion that potential competitors of that company would be subject to injunctions or law suits if they were to market a product containing Manapol® after obtaining a license from DelSite. All intellectual property related to Manapol® is owned by DelSite. There are no current exclusive licensing agreements for Manapol® raw material or for the trademark Manapol®. Our business model has changed. Going forward we will license for single or multiple fields of use, for single or multiple DSHEA claims, for manufacturing or use in individual countries or territories, or for single product lines like drinks or multiple dosage forms."

Clinicians in some African countries are using pure Manapol® powder to enhance immune function in patients with impaired immune systems.

The spokesperson added that "other DelSite 'product by process' raw materials such as Acemannan Hydrogel™ for wound healing and dental care, HydroPol™ for cosmetic and nutraceutical use, VeraPol™ for nutraceutical, as well as Acemannan Immunostimulant™, a USDA approved biologic for the treatment of certain cancers in cats and dogs, will also be licensed."

Interested parties can call Mr. Robert Schnitzius, DelSite's CFO and acting CEO, at (972) 518-1300.

About DelSite

DelSite, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company with a core technology based on naturally occurring complex carbohydrates. DelSite also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. DelSite is developing its proprietary GelSite® technology designed to provide controlled release of peptide and protein-based drugs. More than 130 patents in 26 countries protect its technology.

Certain statements in this release concerning DelSite may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


For Information, Contact:
Robert W. Schnitzius
Acting President and CEO
(972) 518-1300



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->